The Shareholders Foundation announces that an investigation on behalf of investors, who currently hold shares of Cubist Pharmaceuticals Inc (NASDAQ:CBST), was launched concerning whether the takeover of Cubist Pharmaceuticals Inc by Merck for $102 per share is unfair to NASDAQ:CBST stockholders.
Investors who purchased shares of Cubist Pharmaceuticals Inc (NASDAQ:CBST) and currently hold any of those NASDAQ:CBST shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain officers and directors of Cubist Pharmaceuticals Inc breached their fiduciary duties owed to NASDAQ:CBST investors in connection with the proposed acquisition.
On December 8, 2014, Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) announced that the companies have entered into an agreement under which Merck will acquire Cubist for $102 per share in cash.
However, the investigation concerns whether the offer is unfair to NASDAQ:CBST stockholders. More specifically, the investigation concerns whether the Cubist Pharmaceuticals Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders’ best interests in connection with the proposed sale.
On December 18, 204, NASDAQ:CBST shares closed at $97.77 per share.
Those who are current investors in Cubist Pharmaceuticals Inc shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com